{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:00:44Z","timestamp":1764997244127},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Treat-to-target (T2T) is an emerging management strategy in axial spondyloarthritis (axSpA). The concept was originally based on evidence from other chronic conditions, such as hypertension, diabetes and hypothyroidism, as well as some rheumatic diseases, such as rheumatoid arthritis and gout. The purpose of this review is to discuss the arguments against and in favour of adopting a T2T strategy in the management of axSpA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>International groups have recommended a T2T strategy in axSpA. Inactive disease according to the Ankylosing Spondylitis Disease Activity Score (ASDAS) has been suggested as a potential target. Achievement of ASDAS inactive disease has been associated with less progression of radiographic damage in several studies. Evidence for the benefit of a T2T approach has been published in psoriatic arthritis, a form of spondyloarthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Observational evidence suggests that a T2T approach might be beneficial in axSpA. However, data from a prospective randomized study proving the efficacy of a T2T strategy compared to routine care are still lacking. Moreover, the cost-effectiveness of such strategy in clinical practice also needs to be tested. The target will need to be useful and feasible in both clinical practice and clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000625","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T10:47:20Z","timestamp":1557744440000},"page":"344-348","source":"Crossref","is-referenced-by-count":19,"title":["Treat-to-target in axial spondyloarthritis: gold standard or fools\u2019 gold?"],"prefix":"10.1097","volume":"31","author":[{"given":"Pedro M.","family":"Machado","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University College London Hospitals NHS Foundation Trust"},{"name":"Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust"},{"name":"Centre for Rheumatology and MRC Centre for Neuromuscular Diseases, University College London, London, UK"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.2010.884","article-title":"Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease","volume":"304","author":"Cooper-DeHoff","year":"2010","journal-title":"JAMA"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","article-title":"Overdiagnosis and overtreatment in rheumatology: a little caution is in order","volume":"77","author":"Landewe","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/acr.23293","article-title":"Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial","volume":"70","author":"O\u2019Dwyer","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.berh.2014.10.004","article-title":"Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis","volume":"28","author":"Machado","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1136\/annrheumdis-2014-206773","article-title":"CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up","volume":"74","author":"Berg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3899\/jrheum.131003","article-title":"The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial","volume":"41","author":"van der Heijde","year":"2014","journal-title":"J Rheumatol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","article-title":"ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with nonradiographic axial spondyloarthritis","volume":"55","author":"van der Heijde","year":"2016","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:38:22Z","timestamp":1693291102000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000625","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}